Author(s):
Karina Laxman Yadav, Neha Desai, Anuradha Prajapati, Sachin Narkhede, Sailesh Luhar
Email(s):
yadav1212karan@gmail.com
DOI:
10.52711/2231-5691.2025.00012 
Address:
Karina Laxman Yadav1*, Neha Desai2, Anuradha Prajapati2, Sachin Narkhede2, Sailesh Luhar2
1Smt. B.N.B. Swaminarayan Pharmacy College, Gujarat Technological University, Salvav, Vapi, Gujarat, India, 396191.
2Department of Pharmaceutics, Smt. BNB Swaminarayan Pharmacy College, Gujarat Technological University, Salvav, Vapi, Gujarat, India, 396191.
*Corresponding Author
Published In:
Volume - 15,
Issue - 1,
Year - 2025
ABSTRACT:
This comprehensive review article gives the information about the importance about AI in drug repurposing for complex diseases. The increasing prevalence of complicated diseases such as infectious diseases, neurological disorders, and cardiovascular problems calls for the development of novel therapeutic approaches. Conventional medication development is expensive and time-consuming; years of study and clinical trials are frequently needed. AI-enabled medication repurposing has surfaced as a viable method to accelerate the process in this regard. This methodology leverages artificial intelligence (AI) technology, including machine learning and natural language processing, to explore the possibilities of currently licensed drugs for novel therapeutic applications. The present level of AI-driven medication repurposing is examined in this review, with an emphasis on the benefits it offers over conventional techniques and how quickly it could lead to the discovery of new treatments. Key AI strategies, effective case studies, and the shift from preclinical to clinical research are covered. It also tackles difficulties including interpretability of models, data quality, and regulatory concerns. All things considered, AI-enabled drug repurposing is a revolutionary strategy for creating more efficient and reasonably priced treatments for complicated illnesses.
Cite this article:
Karina Laxman Yadav, Neha Desai, Anuradha Prajapati, Sachin Narkhede, Sailesh Luhar. From Bench to Bedside: AI-Enabled Drug Repurposing for Innovative Therapies in Complex Diseases. Asian Journal of Pharmaceutical Research. 2025; 15(1):72-6. doi: 10.52711/2231-5691.2025.00012
Cite(Electronic):
Karina Laxman Yadav, Neha Desai, Anuradha Prajapati, Sachin Narkhede, Sailesh Luhar. From Bench to Bedside: AI-Enabled Drug Repurposing for Innovative Therapies in Complex Diseases. Asian Journal of Pharmaceutical Research. 2025; 15(1):72-6. doi: 10.52711/2231-5691.2025.00012 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-1-12
REFERENCES:
1. Lalu Muhammad Irham, Zalik Nuryana, Dyah Aryani Perwitasari, Yudha Rizky Nuari, Made Ary Sarasmita, Wirawan Adikusuma, Haafizah Dania, Rita Maliza, Rocky Cheung. Worldwide Publication Trends of Drug Repurposing and Drug Repositioning in the Science of Medicine (2003-2022). Research Journal of Pharmacy and Technology. 2023; 16(3): 1333-1. doi: 10.52711/0974-360X.2023.00219.
2. Sirota, M., et al., Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science Translational Medicine. 2011. 3(96): p. 96ra77. https://doi.org/10.1126/scitranslmed.3001318.
3. Ayyar, P. and U. Subramanian, Repurposing – second life for drugs. Pharmacia. 2022. 69(1): p. 51-59. https://doi.org/10.3897/pharmacia.69.e72548.
4. Langedijk, J., et al., Drug repositioning and repurposing: terminology and definitions in literature. Drug Discovery Today, 2015. 20(8): p.1027 34 https://doi.org/10.1016/j.drudis.2015.05.001.
5. Sahragardjoonegani, B., et al., Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. Journal of Pharmaceutical Policy and Practice, 2021. 14(1): p. 3. https://doi.org/10.1186/s40545-020-00282-8.
6. Ayyar, P. and U. Subramanian, Repurposing – second life for drugs. Pharmacia, 2022. 69(1): p. 51-59. https://doi.org/10.3897/pharmacia.69.e72548.
7. Hay, M., et al., Clinical development success rates for investigational drugs. Nature Biotechnology, 2014. 32(1): p. 40-51. https://doi.org/10.1038/nbt.2786.
8. Annie Persaud. Using the EFQM Excellence Model Within Health Care, a Practical Guide to Success. International J. Health Care Quality Assurance. 2002; 15 (4): 141.
9. Charles A. Cianfrani, John E. ISO 9001: 2008 Explained, Third Edition, ASQ store; north America. P. 12.
10. Muralidharan, N., et al., Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. Journal of Biomolecular Structure and Dynamics. 2021. 39(7): p. 2673-2678. https://doi.org/10.1080/07391102.2020.1752802.
11. Pushpakom, S., et al., Drug repurposing: progress, challenges and recommendations. Nature Reviews. Drug Discovery, 2019. 18(1): p. 41-58. https://doi.org/10.1038/nrd.2018.168
12. Centers for Disease Control and Prevention (CDC). Update: Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep. 2003; 52(12): 241-6.
13. Buchholz U, Müller MA, Nitsche A, Sanewski A, Wevering N, Bauer-Balci T, et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill. 2013; 18: 20406.
14. Krishnamurthy, Nithya and Grimshaw, Alyssa and Axson, Sydney and Choe, Sung and Miller, Jennifer. (2021). Why promising drugs are shelved and barriers and facilitators to re-purposing them: A systematic literature review. 10.1101/2021.09.28.21264254.
15. Deng J, Yang Z, Ojima I, Samaras D, Wang F. Artificial intelligence in drug discovery: applications and techniques. Brief Bioinform. 2022; Jan 17; 23(1): bbab430. doi: 10.1093/bib/bbab430. PMID: 34734228.